Separating dose schedule from disease biology in CD19 CAR T-cell therapy. Comment on: “A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma” by Yushan Jin, Yuan Fang and Yao Yao

Retraction Notice due to paper mill activity of the paper:
Comment with doi https://doi.org/10.3324/haematol.2026.301607
Separating dose schedule from disease biology in CD19 CAR T-cell therapy. Comment on: “A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma”

The Comment with doi https://doi.org/10.3324/haematol.2026.301607 has been retracted by the Editor-in-Chief of Haematologica. For details on our editorial standards, please refer to the Haematologica policy on the misuse of Artificial Intelligence in submitted manuscripts (https://haematologica.org/our-policies).

This comment was found to be nearly identical to other comments submitted by different authors discussing various original articles in Haematologica. Following an internal investigation, it was determined that this contribution originated from a coordinated network and exhibited clear indicators of systematic manipulation (paper mill activity). The authors were contacted regarding these concerns but failed to respond. Consequently, the Editor concluded that the comment is non-authentic, standardized, and lacks legitimate scientific rationale. The authors have been formally notified of this retraction.

To whom correspondence should be addressed: office@haematologica.org

doi:10.3324/haematol.2026.302412